These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32307859)

  • 1. Non-invasive diagnosis of non-alcoholic steatohepatitis and advanced fibrosis in Japan: A targeted literature review.
    Eguchi Y; Wong G; Akhtar O; Sumida Y
    Hepatol Res; 2020 Jun; 50(6):645-655. PubMed ID: 32307859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A structured review of published works.
    Eguchi Y; Wong G; Lee IH; Akhtar O; Lopes R; Sumida Y
    Hepatol Res; 2021 Jan; 51(1):19-30. PubMed ID: 33091191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review.
    Eguchi Y; Wong G; Lee EI; Akhtar O; Lopes R; Sumida Y
    JGH Open; 2020 Oct; 4(5):808-817. PubMed ID: 33102749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of artificial intelligence in non-alcoholic fatty liver disease and liver fibrosis: a systematic review and meta-analysis.
    Decharatanachart P; Chaiteerakij R; Tiyarattanachai T; Treeprasertsuk S
    Therap Adv Gastroenterol; 2021; 14():17562848211062807. PubMed ID: 34987607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS.
    Smiderle CA; Coral GP; DE Carli LA; Mattos AA; Mattos AZ; Tovo CV
    Arq Gastroenterol; 2021; 58(2):139-144. PubMed ID: 34231659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments.
    Kwok R; Tse YK; Wong GL; Ha Y; Lee AU; Ngu MC; Chan HL; Wong VW
    Aliment Pharmacol Ther; 2014 Feb; 39(3):254-69. PubMed ID: 24308774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.
    Anstee QM; Lawitz EJ; Alkhouri N; Wong VW; Romero-Gomez M; Okanoue T; Trauner M; Kersey K; Li G; Han L; Jia C; Wang L; Chen G; Subramanian GM; Myers RP; Djedjos CS; Kohli A; Bzowej N; Younes Z; Sarin S; Shiffman ML; Harrison SA; Afdhal NH; Goodman Z; Younossi ZM
    Hepatology; 2019 Nov; 70(5):1521-1530. PubMed ID: 31271665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis.
    Kugelmas M; Noureddin M; Gunn N; Brown K; Younossi Z; Abdelmalek M; Alkhouri N
    Liver Int; 2023 May; 43(5):964-974. PubMed ID: 36864668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
    Arora A; Sharma P
    J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience.
    Rath MM; Panigrahi MK; Pattnaik K; Bhuyan P; Kar SK; Misra B; Misra D; Meher C; Agrawal O; Rath J; Singh SP
    J Clin Exp Hepatol; 2016 Dec; 6(4):291-296. PubMed ID: 28003718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stratifying Non-alcoholic Steatohepatitis With the Non-invasive Ultrasound Markers Shear Wave Dispersion Slope and Shear Wave Velocity: An Animal Study.
    Kong W; Tang Y; Liu L; Zhang G; Liu Y; Liu J
    Ultrasound Med Biol; 2022 Dec; 48(12):2442-2448. PubMed ID: 36096895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
    Vilar-Gomez E; Chalasani N
    J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
    Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E
    Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.
    Boyle M; Tiniakos D; Schattenberg JM; Ratziu V; Bugianessi E; Petta S; Oliveira CP; Govaere O; Younes R; McPherson S; Bedossa P; Nielsen MJ; Karsdal M; Leeming D; Kendrick S; Anstee QM
    JHEP Rep; 2019 Sep; 1(3):188-198. PubMed ID: 32039369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.